Show me anything else they were provided?? It was all in or attached to the JAMA Oncology. No details of the external comparator trials (screeners, protocols), no FDA partial hold details, very limited description of the statistical manipulation of the nOS endpoint for crossover dosing confounding (buried in the SAP). Surely not forthcoming on the trial issues like post hoc, data dredged recurrent OS endpoint
Market Data 
Markets 
AI
